ROLE OF FECAL CALPROTECTIN IN DIFFERENTIATION OF INFLAMMATORY BOWEL DISEASES IN PATIENTS COMPLAINING OF ABDOMINAL SYMPTOMS AND REFERRED FOR COLONOSCOPY

Authors

  • Trifa A. Mahmood College of Medicine, University of Sulaimani, Kurdistan Region, Iraq. & Kurdistan Centre of Gastroenterology and Hepatology (KCGH), Sulaymaniyah, Kurdistan Region, Iraq.
  • Mohammed O. Mohammed College of Medicine, University of Sulaimani, Kurdistan Region, Iraq. & Kurdistan Centre of Gastroenterology and Hepatology (KCGH), Sulaymaniyah, Kurdistan Region, Iraq.
  • Dana T. Gharib Kurdistan Centre of Gastroenterology and Hepatology (KCGH), Sulaymaniyah, Kurdistan Region, Iraq.
  • Taha A. Mohamad College of Medicine, University of Sulaimani, Kurdistan Region, Iraq. & Kurdistan Centre of Gastroenterology and Hepatology (KCGH), Sulaymaniyah, Kurdistan Region, Iraq.
  • Muhsin A. Mohammed Kurdistan Centre of Gastroenterology and Hepatology (KCGH), Sulaymaniyah, Kurdistan Region, Iraq.
  • Araz L. Rahim Kurdistan Centre of Gastroenterology and Hepatology (KCGH), Sulaymaniyah, Kurdistan Region, Iraq.

DOI:

https://doi.org/10.17656/jsmc.10285

Keywords:

Inflammatory bowel disease, Fecal calprotectin, Colonoscopy, Sulaimaniyah

Abstract

Background 

The difficulty in differentiating functional gastrointestinal disorders and inflammatory bowel diseases in patients presenting with abdominal symptoms direct us to the use of fecal inflammatory biomarkers that are specific to intestinal inflammation.

Objectives 

To assess the benefits of fecal calprotectin (FC) in patients presenting with lower abdominal symptoms. Also, correlating the FC and CRP titer with abdominal pain severity.

Patients and Methods

Prospective cross-sectional study in Kurdistan Center for Gastroenterology and Hepatology (KCGH), Sulaimaniyah city, Northern Iraq. A total of 174 patients with IBS according to Rome IV criteria, who visited KCGH, met the inclusion criteria. FC titer measured before colonoscopy appointment, abdominal pain severity scored according to visual scale, and colonoscopy performed by a specialized gastroenterologist. 

Results

The FC level was below 50ug/g for 91.3% of patients with normal endoscopy; all of the IBD cases had FC level above 100ug/g. Seven of the eight patients with non-inflamed polyp or diverticuli had an FC level of less than 50ug/g. Moreover, in this study, the CRP level is also significantly higher among IBD cases than in patients with normal colonoscopy. 

Conclusion

FC titer is a useful measure before the decision for colonoscopy especially in cases not having alarm symptoms and other comorbidities. FC and CRP level is associated with the severity of abdominal pain.

References

Holtedahl K, Vedsted P, Borgquist L, Donker GA, Buntinx F, Weller D, et al. Abdominal symptoms in general practice: Frequency, cancer suspicions raised, and actions taken by GPs in six European countries. Cohort study with prospective registration of cancer. Heliyon. 2017;3(6):e00328. DOI: https://doi.org/10.1016/j.heliyon.2017.e00328

Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology. 2016;150(6):1262-79. e2. DOI: https://doi.org/10.1053/j.gastro.2016.02.032

Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clinical gastroenterology and hepatology. 2012;10(7):712-21. e4. DOI: https://doi.org/10.1016/j.cgh.2012.02.029

Linedale EC, Andrews JM. Diagnosis and management of irritable bowel syndrome: A guide for the generalist. Medical Journal of Australia. 2017;207(7):309-15. DOI: https://doi.org/10.5694/mja17.00457

Linedale EC, Shahzad MA, Kellie AR, Mikocka-Walus A, Gibson PR, Andrews JM. Referrals to a tertiary hospital: a window into clinical management issues in functional gastrointestinal disorders. JGH Open. 2017;1(3):84-91. DOI: https://doi.org/10.1002/jgh3.12015

Masuy I, Pannemans J, Tack J. Irritable bowel syndrome: diagnosis and management. Minerva gastroenterologica e dietologica. 2019. DOI: https://doi.org/10.23736/S1121-421X.19.02640-0

Ricciuto A, Griffiths AM. Clinical value of fecal calprotectin. Critical reviews in clinical laboratory sciences. 2019;56(5):307-20. DOI: https://doi.org/10.1080/10408363.2019.1619159

An YK, Prince D, Gardiner F, Neeman T, Linedale EC, Andrews JM, et al. Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta-analysis. Medical Journal of Australia. 2019;211(10):461-7. DOI: https://doi.org/10.5694/mja2.50384

Mari A, Baker FA, Mahamid M, Yacoob A, Sbeit W, Khoury T. Clinical utility of fecal calprotectin: potential applications beyond inflammatory bowel disease for the primary care physician. Annals of gastroenterology. 2019;32(5):425. DOI: https://doi.org/10.20524/aog.2019.0394

Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106. DOI: https://doi.org/10.1136/gutjnl-2019-318484

Chang MH, Chou JW, Chen SM, Tsai MC, Sun YS, Lin CC, et al. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome. Molecular medicine reports. 2014;10(1):522-6. DOI: https://doi.org/10.3892/mmr.2014.2180

Caviglia GP, Pantaleoni S, Touscoz GA, Adriani A, Rosso C, Smedile A, et al. Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. Scandinavian journal of gastroenterology. 2014;49(12):1419-24. DOI: https://doi.org/10.3109/00365521.2014.934913

Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert review of gastroenterology & hepatology. 2014;8(2):197-210. DOI: https://doi.org/10.1586/17474124.2014.869476

Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health technology assessment (Winchester, England). 2013;17(55):xv-xix, 1-211. DOI: https://doi.org/10.3310/hta17550

Gavin DR, Valori RM, Anderson JT, Donnelly MT, Williams JG, Swarbrick ET. The national colonoscopy audit: a nationwide assessment of the quality and safety of colonoscopy in the UK. Gut. 2013;62(2):242-9. DOI: https://doi.org/10.1136/gutjnl-2011-301848

Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. Clinical and experimental gastroenterology. 2016;9:21-9. DOI: https://doi.org/10.2147/CEG.S51902

Carmona-Sánchez R, Icaza-Chávez M, Bielsa-Fernández M, Gómez-Escudero O, Bosques-Padilla F, Coss-Adame E, et al. The Mexican consensus on irritable bowel syndrome. Revista de Gastroenterología de México (English Edition). 2016;81(3):149-67. DOI: https://doi.org/10.1016/j.rgmxen.2016.01.004

Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016.

Lacy B, Patel N. Rome criteria and a diagnostic approach to irritable bowel syndrome. Journal of clinical medicine. 2017;6(11):99. DOI: https://doi.org/10.3390/jcm6110099

Spiegel B, Bolus R, Harris L, Lucak S, Naliboff B, Esrailian E, et al. Measuring IBS patient reported outcomes with an abdominal pain numeric rating scale: results from the proof cohort. Alimentary pharmacology & therapeutics. 2009;30(11-12):1159. DOI: https://doi.org/10.1111/j.1365-2036.2009.04144.x

McFarlane M, Chambers S, Dhaliwal A, Lee B, Sung E, Nwokolo C, et al. Is NICE too optimistic about savings from faecal calprotectin testing? Value in Health. 2015;18(7):A623. DOI: https://doi.org/10.1016/j.jval.2015.09.2189

McLean MH, Murray GI, Stewart KN, Norrie G, Mayer C, Hold GL, et al. The inflammatory microenvironment in colorectal neoplasia. PLoS One. 2011;6(1):e15366. DOI: https://doi.org/10.1371/journal.pone.0015366

Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. The American journal of gastroenterology. 2015;110(3):444. DOI: https://doi.org/10.1038/ajg.2015.6

Lee YW, Lee K-M, Lee JM, Chung YY, Kim DB, Kim YJ, et al. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity. The Korean journal of internal medicine. 2019;34(1):72. DOI: https://doi.org/10.3904/kjim.2016.324

Sharbatdaran M, Holaku A, Kashifard M, Bijani A, Firozjahi A, Hosseini A, et al. Fecal calprotectin Level in patients with IBD and noninflammatory disease of colon: a study in Babol, Northern, Iran. Caspian journal of internal medicine. 2018;9(1):60.

Manceau H, Chicha-Cattoir V, Puy H, Peoc’h K. Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clinical Chemistry and Laboratory Medicine (CCLM). 2017;55(4):474-83. DOI: https://doi.org/10.1515/cclm-2016-0522

Petryszyn P, Staniak A, Wolosianska A, Ekk-Cierniakowski P. Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: meta-analysis. European journal of gastroenterology & hepatology. 2019;31(11):1306-12. DOI: https://doi.org/10.1097/MEG.0000000000001509

Sipponen T, Savilahti E, Kolho K-L, Nuutinen H, Turunen U, Färkkilä M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory bowel diseases. 2008;14(1):40-6. DOI: https://doi.org/10.1002/ibd.20312

Von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. American Journal of Gastroenterology. 2007;102(4):803-13. DOI: https://doi.org/10.1111/j.1572-0241.2007.01126.x

Van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. Bmj. 2010;341:c3369. DOI: https://doi.org/10.1136/bmj.c3369

Freeman K, Willis BH, Fraser H, Taylor-Phillips S, Clarke A. Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy. BMJ open. 2019;9(3):e027428. DOI: https://doi.org/10.1136/bmjopen-2018-027428

Conroy S, Hale MF, Cross SS, Swallow K, Sidhu RH, Sargur R, et al. Unrestricted faecal calprotectin testing performs poorly in the diagnosis of inflammatory bowel disease in patients in primary care. Journal of clinical pathology. 2018;71(4):316-22. DOI: https://doi.org/10.1136/jclinpath-2017-204506

Moayyedi P, Andrews CN, MacQueen G, Korownyk C, Marsiglio M, Graff L, et al. Canadian Association of Gastroenterology clinical practice guideline for the management of irritable bowel syndrome (IBS). Journal of the Canadian Association of Gastroenterology. 2019;2(1):6-29. DOI: https://doi.org/10.1093/jcag/gwy071

Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57(11):1518-23. DOI: https://doi.org/10.1136/gut.2007.146357

Fagan EA, Dyck RF, Maton PN, Hodgson HJ, Chadwick VS, Petrie A, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest. 1982;12(4):351-9. DOI: https://doi.org/10.1111/j.1365-2362.1982.tb02244.x

Poullis AP, Zar S, Sundaram KK, Moodie SJ, Risley P, Theodossi A, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation-and diarrhoea-predominant functional bowel disorders. European journal of gastroenterology & hepatology. 2002;14(4):409-12. DOI: https://doi.org/10.1097/00042737-200204000-00013

Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflammatory bowel diseases. 2008;14(1):32-9. DOI: https://doi.org/10.1002/ibd.20275

Ricanek P, Brackmann S, Perminow G, Lyckander LG, Sponheim J, Holme O, et al. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scandinavian journal of gastroenterology. 2011;46(9):1081-91. DOI: https://doi.org/10.3109/00365521.2011.584897

Van Limbergen J, Russell RK, Nimmo ER, Ho GT, Arnott ID, Wilson DC, et al. Genetics of the innate immune response in inflammatory bowel disease. Inflammatory bowel diseases. 2007;13(3):338-55. DOI: https://doi.org/10.1002/ibd.20096

Schoepfer AM, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflammatory bowel diseases. 2013;19(2):332-41. DOI: https://doi.org/10.1097/MIB.0b013e3182810066

Beattie R, Walker-Smith J, Murch S. Indications for investigation of chronic gastrointestinal symptoms. Archives of disease in childhood. 1995;73(4):354-5. DOI: https://doi.org/10.1136/adc.73.4.354

Loftus EV, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterology Clinics of North America. 2002;31(1):1-20. DOI: https://doi.org/10.1016/S0889-8553(01)00002-4

Taleban S, Colombel JF, Mohler MJ, Fain MJ. Inflammatory bowel disease and the elderly: a review. Journal of Crohn's & colitis. 2015;9(6):507-15. DOI: https://doi.org/10.1093/ecco-jcc/jjv059

Ashktorab H, Panchal H, Shokrani B, Paydar M, Sanderson A, Lee EL, et al. Association between Diverticular Disease and Pre-Neoplastic Colorectal Lesions in an Urban African-American Population. Digestion. 2015;92(2):60-5. DOI: https://doi.org/10.1159/000376574

Peery AF, Barrett PR, Park D, Rogers AJ, Galanko JA, Martin CF, et al. A high-fiber diet does not protect against asymptomatic diverticulosis. Gastroenterology. 2012;142(2):266-72.e1. DOI: https://doi.org/10.1053/j.gastro.2011.10.035

Kostas A, Siakavellas SI, Kosmidis C, Takou A, Nikou J, Maropoulos G, et al. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World journal of gastroenterology. 2017;23(41):7387. DOI: https://doi.org/10.3748/wjg.v23.i41.7387

Kwapisz L, Gregor J, Chande N, Yan B, Ponich T, Mosli M. The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease. Scandinavian journal of gastroenterology. 2017;52(8):846-50. DOI: https://doi.org/10.1080/00365521.2017.1315740

Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000;47(4):506-13. DOI: https://doi.org/10.1136/gut.47.4.506

Naismith GD, Smith LA, Barry SJ, Munro JI, Laird S, Rankin K, et al. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease. Aliment Pharmacol Ther. 2013;37(6):613-21. DOI: https://doi.org/10.1111/apt.12221

Published

2021-03-21

How to Cite

1.
Mahmood T, Mohammed M, Gharib D, Mohamad T, Mohammed M, Rahim A. ROLE OF FECAL CALPROTECTIN IN DIFFERENTIATION OF INFLAMMATORY BOWEL DISEASES IN PATIENTS COMPLAINING OF ABDOMINAL SYMPTOMS AND REFERRED FOR COLONOSCOPY. JSMC [Internet]. 2021 Mar. 21 [cited 2024 Jul. 25];11(1):33-44. Available from: https://jsmc.univsul.edu.iq/index.php/jsmc/article/view/jsmc-10285

Similar Articles

1-10 of 153

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

<< < 1 2 3 > >>